Have any questions? [email protected] +86-21-58998590
Structure search

Bleomycin (sulfate)


CAS No. : 9041-93-4

(Synonyms: Bleomycin sulfate)

9041-93-4
Price and Availability of CAS No. : 9041-93-4
Size Price Stock
5mg $108 In-stock
10mg $168 In-stock
25mg $385 In-stock
50mg $672 In-stock
100mg $1000 In-stock
200mg $1505 In-stock
500mg $3010 In-stock
1g $4515 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-17565
M.Wt: 1000.00
Formula: N/A
Purity: >98 %
Solubility: H2O : 255 mg/mL (ultrasonic;warming);DMSO : 41.67 mg/mL (ultrasonic)
Introduction of 9041-93-4 :

Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic[1]. IC50 & Target:DNA/RNA Synthesis[1] In Vitro: Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1].
The IC50 value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM); IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively[2].
Bleomycin sulfate (50, 100 μM; for 24, 48 h) induce pulmonary fibrosis in RLE-6TN cell (50 μM) and A549 cell (100 μM)[4].
In Vivo: Bleomycin sulfate can be used to induce pulmonary fibrosis models. After administration via intramuscular, subcutaneous, intraperitoneal, or intrapleural routes, Bleomycin sulfate is rapidly absorbed and reaches peak plasma concentrations in approximately 60 minutes. Less than 1% of intravenously injected Bleomycin sulfate binds to plasma proteins, ensuring high bioavailability. The mean plasma clearance rate of Bleomycin sulfate is about 70 mL/min/m2, indicating high plasma elimination and urinary excretion rates2[6].

Induction of Pulmonary Fibrosis[7]
Background
Bleomycin sulfate can lead to lung patchy parenchymal inflammation, epithelial cell injury with reactive hyperplasia, epithelial-mesenchymal transition, activation and differentiation of fibroblasts to myofibroblasts, and basement membrane and alveolar epithelium injures. The experimental use of Bleomycin sulfate is to induce pulmonary fibrosis animal models.
Specific Modeling Methods
Mice: C57BL/6 • 12-week-old
Administration: 3-5 mg/kg • intratracheal administration • sprays on day one
Note
The mice were housed in separate stainless-steel cages (six mice per cage) in a temperature-controlled environment (20-24°C) on 12 h light-dark cycles with unrestricted access to food and water.
Modeling Indicators
Body quality changes: The appetite activity is reduced, with the fur less shiny, the spirits being lethargic, and the bodyweight decreasing. Showed shortness of breath, coughing, and noisy.
Lung changes: Increased fibrotic consolidations, non-aerated lung area, and high-density lung area. Pulmonary function decreased.
Molecular changes: Increased indicators: TGF-β1, TNF-α, IL-6, and GM-CSF in bronchoalveolar lavage fluid.
Correlated Product(s): Bleomycin hydrochloride (HY-17565A)
Opposite Product(s): Neotuberostemonine (HY-N3196)

Your information is safe with us.